Peptides for Scar Healing — Keloids, Hypertrophic Scars & Post-Surgical

Scarring is one of the most common outcomes of skin injury, yet effective treatments remain limited. Standard options — silicone sheets, corticosteroid injections, laser therapy — help but rarely eliminate scars. Peptides have emerged as a compelling research area because they interact with the signaling pathways that govern wound healing and scar formation. The evidence varies widely, so understanding what each peptide does and where its data stands matters before drawing conclusions.

This article is educational content and is not medical advice. Consult a qualified healthcare professional before using any peptide for scar treatment.

The biology of scar formation

Wound healing proceeds through three overlapping phases, and disruptions at any stage can produce abnormal scars.

Inflammation, proliferation, and remodeling

During inflammation (days 1-5), neutrophils and macrophages clear debris while cytokines like IL-1, IL-6, and TNF-alpha coordinate the response. Excessive inflammation sets the stage for abnormal scarring. In proliferation (days 5-21), fibroblasts deposit extracellular matrix — predominantly type III collagen — and new blood vessels form. During remodeling (weeks to months), type III collagen is replaced by stronger type I collagen. Matrix metalloproteinases (MMPs) break down disorganized collagen while new fibers are laid down in more orderly patterns.

Why keloids and hypertrophic scars form

Pathological scarring occurs when fibroblasts overproduce collagen and the remodeling phase fails to break it down. The key driver is dysregulated TGF-beta signaling — elevated TGF-beta1 and TGF-beta2 promote excess deposition, while TGF-beta3 (which favors scarless healing) is deficient. Keloid fibroblasts also show reduced MMP activity. This imbalance between collagen synthesis and degradation is the core target for peptide-based interventions.

GHK-Cu: the most studied scar-relevant peptide

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma in the 1970s, where its concentration declines with age.

Mechanism of action

GHK-Cu delivers bioavailable copper — an essential cofactor for lysyl oxidase (which crosslinks collagen) and superoxide dismutase (a key antioxidant). It upregulates MMP-2 and MMP-9, promoting breakdown of disorganized scar collagen. Crucially, it stimulates decorin synthesis, a proteoglycan that sequesters TGF-beta1 — directly addressing the central driver of pathological scarring. Gene expression studies show GHK-Cu modulates over 4,000 human genes, upregulating tissue remodeling genes while downregulating those linked to fibrosis.

Human evidence

GHK-Cu has human data, though not from large RCTs on scar treatment specifically. Controlled wound-healing studies demonstrate accelerated closure and improved cosmetic outcomes with topical application. Post-procedure studies (after laser resurfacing and chemical peels) show reduced erythema and faster re-epithelialization. These results are encouraging but come from small studies with varying formulations. Its molecular weight (~403 Da) allows reasonable skin penetration in topical formulations (typically 0.1-1% concentration).

BPC-157: preclinical anti-fibrotic data

BPC-157 is a 15-amino-acid peptide derived from human gastric juice protein. Its wound-healing properties have been studied extensively — but almost entirely in animal models.

In rodent studies, BPC-157 accelerates healing by promoting angiogenesis via VEGF upregulation and the FAK-paxillin pathway. It modulates the nitric oxide system and has shown anti-fibrotic effects in models of liver, gut, and skin fibrosis — reducing excessive collagen deposition and producing more organized collagen architecture.

Important: BPC-157 has no published human clinical trials for scar treatment. All data is preclinical. It was also added to the FDA's restricted compounding list in 2023. These results should be viewed as hypothesis-generating, not clinical evidence.

AHK copper peptide

AHK (alanyl-histidyl-lysine) is a tripeptide structurally related to GHK-Cu that also binds copper ions. Found naturally in the extracellular matrix, AHK stimulates type I and type III collagen synthesis and promotes glycosaminoglycan production. In vitro studies show collagen-stimulating activity comparable to GHK-Cu. However, AHK has considerably less published research — most data comes from fibroblast assays and cosmetic testing rather than controlled clinical trials. It should be considered less validated for scar-specific applications.

Oral collagen peptides

Hydrolyzed collagen supplements take a different approach. When ingested, collagen breaks down into dipeptides like prolyl-hydroxyproline (Pro-Hyp) that are absorbed intact and accumulate in skin tissue. There, they stimulate fibroblasts to increase collagen, hyaluronic acid, and elastin production — acting as false degradation signals that trigger compensatory synthesis.

Several RCTs show oral collagen (2.5-10 g/day for 8-12 weeks) improves skin elasticity and dermal collagen density. However, these studies assessed general skin quality in aging populations, not scar remodeling specifically. Oral collagen may support overall dermal turnover but should not be expected to target specific scars.

Topical vs. systemic delivery

Topical application delivers peptides directly to the scar with minimal systemic exposure — ideal for surface scars but limited by penetration depth. Microneedling, iontophoresis, and liposomal encapsulation can improve delivery into deeper dermis.

Systemic delivery (injection, oral supplementation) achieves broader distribution but lacks site specificity. For deep surgical scars that topical products cannot reach, systemic approaches may be the only option, though evidence is minimal.

In practice, topical delivery enhanced by microneedling is the best-supported approach, particularly for GHK-Cu.

Anti-fibrotic mechanisms

The most therapeutically interesting peptide property for scars is anti-fibrotic activity. Key mechanisms include: TGF-beta modulation — GHK-Cu upregulates decorin, which sequesters pro-fibrotic TGF-beta1; MMP activation — copper peptides increase metalloproteinase activity to break down excess collagen; inflammation resolution — both GHK-Cu and BPC-157 (in animal models) show anti-inflammatory effects; and collagen organization — some peptides promote aligned fiber architecture rather than the disordered bundles found in keloids.

These mechanisms suggest peptides may be most effective early in healing, during or shortly after the inflammatory phase, to steer wounds toward normal remodeling.

Limitations

Most evidence is preclinical. BPC-157's scar data is entirely from animal studies. Even GHK-Cu lacks large RCTs for keloid or hypertrophic scar treatment.

Scar biology is highly individual. Genetics, scar location, skin type, and injury mechanism all influence outcomes. Keloids are notoriously resistant to treatment.

Formulation matters. A peptide's efficacy depends on concentration, stability, and delivery vehicle. Not all commercial products are equivalent.

Timing may be critical. Peptides that modulate remodeling may need application during a specific healing window.

Conclusion

Peptides engage the biological pathways that determine scar quality — collagen turnover, TGF-beta signaling, and MMP-driven remodeling. GHK-Cu has the strongest profile: well-characterized mechanisms, human wound-healing data, and wide availability. BPC-157 shows intriguing preclinical anti-fibrotic properties but lacks human evidence. Oral collagen peptides support general skin health without scar-specific data.

The realistic picture: topical copper peptides are the most evidence-supported option, particularly combined with microneedling for deeper scars. Other peptides remain in earlier validation stages.

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Scar treatment decisions should be made in consultation with a qualified dermatologist or plastic surgeon.